Proteome Sciences Ramps up Revenues to £198K in H1 2007, Looks to Mass Tag Technology for Growth
Proteome Sciences said last week it had increased its revenue to £198,000 [$403,000] for the six months ended June 30, up from £7,000 a year ago, and reduced its loss to £2.32 million from £2.83 million a year ago.
Almost all of the company’s revenues came from the ProteoShop proteomics workflow. As of June 30, Proteome Sciences had £598,173 in cash and cash equivalents.
In July the company received a notice of allowance from the US Patent and Trademark Office for its patent application in isobaric mass labeling for tandem mass tags. It received patents rights to the technology in Europe in the spring. Proteome Sciences also received a notice of intention to grant from the European Patent Office for technology that incorporates isobaric mass tags with peptide structures and various methods of use.
The company is now pursuing licensing agreements with other firms for the technologies
“We intend to complete the license agreements and to have the [technology] product available as soon as possible in the second half of the year,” R.S. Harris, chairman of the company, said in a statement. “The completion of the … licenses will generate substantial revenue for our company.”
Matritech, Sysmex Cancel 2002 Licensing Agreement
Matritech last week announced it and Sysmex have mutually terminated a worldwide license granted to Sysmex for use of Matritech’s NMP 179 cervical cancer technology for automated, non-slide-based laboratory instruments.
As a result, the development of an automated process for the screening of cervical cells by combining the NMP 179 technology with flow cytometry has been discontinued. All rights licensed in the agreement revert to Matritech.
The original deal between the two firms was signed in 2002. Matritech is currently in the process of being acquired by Inverness Medical Innovations [See PM 09/06/07].
ABRF ESRG Seeking Participants, PRG Continuing to Accept Sample Requests
The Association of Biomolecular Resource Facilities’ Edman Sequencing Research Group said this week that test samples for its 2008 study are now available. This year’s study is aimed at determining the difficulty of sequencing through an N-terminal His-tag and to “still be able to determine protein identity,” the group said in its announcement.
Three samples on PVDF membrane will be provided. Participants are asked to sequence each sample one time. Participating laboratories will submit their data electronically to the ESRG for tabulation of results, which will be presented at ABRF’s meeting in Salt Lake City in February.
Those interested in participating in the study can e-mail a request for a sample to [email protected]. Final requests for samples should be made by Oct. 14. Data should be submitted by Dec. 14.
Also, ABRF’s Proteomics Research Group said it is continuing to accept sample requests for its study exploring the use of different approaches to determine qualitative differences between two similar samples. The deadline had been Sept. 28. The group did not announce a new deadline.
More information about the study can be found here.
GWC Technologies Inks Distribution Deal for China with MissionCouver
MissionCouver will become the exclusive distributor of GWC Technologies’ label-free array systems in China, under an agreement announced this week. Financial terms of the deal were not disclosed.
According to Tim Burland, president and CEO of GWC, the agreement marks the first time that the company will have full service, local representation in China for its label-free array products. The agreement includes marketing of GWC’s SPRimager II label-free detection system and the development of novel biomolecular array technologies.
ATP Awards Anima Cell Metrology $1.94M for Protein ID System
Anima Cell Metrology has been awarded $1.94 million to develop a platform for the study and identification of proteins in live cells in real time as part of 56 Advanced Technology Program grants awarded last week by the National Institute of Standards and Technology.
Anima Cell will use its award to develop an in vitro technique for its Protein Synthesis Measurement platform. The funding from ATP is for three years.
Japan's NCRI Uses Proteomics Software in Biomarker Hunt
Japan's National Cancer Research Institute is using Nonlinear Dynamics' 2D gel analysis software in research aimed at discovering and validating biomarkers for cancer diagnostics, the company said this week.
The NCRI is using the company’s Progenesis SameSpots image analysis platform to develop biomarker candidates that would predict response to the cancer therapy gefitinib in lung adenocarcinoma. The project is also planning to identify markers that will predict a patient's risk of cancer recurrence, the company said.
The NCRI’s clinical proteomics group currently runs more than 1,500 2D-DIGE gels per year.
Financial terms of the agreement were not released.